drugset / Trial / NCT01380600
Phase 1b Dose Escalation Study of Intravenous JX-594 in Metastatic, Refractory Colorectal Carcinoma
NaSingle-groupOpen-labelTreatment
Summary
The purpose of this pilot safety study is to evaluate the safety and tolerability of JX-594 (Pexa-Vec) administered intravenously every 2 weeks in colorectal carcinoma patients who are refractory to or intolerant of oxaliplatin, irinotecan, and Erbitux treatments.
Timeline
- Start
- 2010-09-08
- Primary completion
- 2012-10-18
- Completion
- 2012-10-18
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Pexastimogene Devacirepvec | Other / unclassified | 1e+06 unknown | Intravenous |
| Subject | Pexastimogene Devacirepvec | Other / unclassified | 1e+07 unknown | Intravenous |
| Subject | Pexastimogene Devacirepvec | Other / unclassified | 3e+07 unknown | Intravenous |